|
||||||
|
 | |
| |
| |
| |
| |
|
Fusion gene ID: 4814 |
FusionGeneSummary for C1QA_CD74 |
 Fusion gene summary |
| Fusion gene information | Fusion gene name: C1QA_CD74 | Fusion gene ID: 4814 | Hgene | Tgene | Gene symbol | C1QA | CD74 | Gene ID | 712 | 972 |
| Gene name | complement C1q A chain | CD74 molecule | |
| Synonyms | - | DHLAG|HLADG|II|Ia-GAMMA | |
| Cytomap | 1p36.12 | 5q33.1 | |
| Type of gene | protein-coding | protein-coding | |
| Description | complement C1q subcomponent subunit Acomplement C1q chain Acomplement component 1, q subcomponent, A chaincomplement component 1, q subcomponent, alpha polypeptidecomplement component C1q, A chain | HLA class II histocompatibility antigen gamma chainCD74 antigen (invariant polypeptide of major histocompatibility complex, class II antigen-associated)CD74 molecule, major histocompatibility complex, class II invariant chainHLA-DR antigens-associated | |
| Modification date | 20180523 | 20180522 | |
| UniProtAcc | P02745 | P04233 | |
| Ensembl transtripts involved in fusion gene | ENST00000374642, ENST00000402322, | ENST00000377795, ENST00000353334, ENST00000524315, ENST00000009530, | |
| Fusion gene scores | * DoF score | 2 X 3 X 2=12 | 16 X 15 X 5=1200 |
| # samples | 3 | 27 | |
| ** MAII score | log2(3/12*10)=1.32192809488736 effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs). DoF>8 and MAII>0 | log2(27/1200*10)=-2.15200309344505 possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs). DoF>8 and MAII<0 | |
| Context | PubMed: C1QA [Title/Abstract] AND CD74 [Title/Abstract] AND fusion [Title/Abstract] | ||
| Functional or gene categories assigned by FusionGDB annotation | |||
| * DoF score (Degree of Frequency) = # partners X # break points X # cancer types ** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10) |
| Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez |
| Partner | Gene | GO ID | GO term | PubMed ID |
| Tgene | CD74 | GO:0001516 | prostaglandin biosynthetic process | 12782713 |
| Tgene | CD74 | GO:0001934 | positive regulation of protein phosphorylation | 24942581 |
| Tgene | CD74 | GO:0002792 | negative regulation of peptide secretion | 19849849 |
| Tgene | CD74 | GO:0007165 | signal transduction | 12782713 |
| Tgene | CD74 | GO:0008283 | cell proliferation | 12782713 |
| Tgene | CD74 | GO:0033674 | positive regulation of kinase activity | 24942581 |
| Tgene | CD74 | GO:0043066 | negative regulation of apoptotic process | 12782713 |
| Tgene | CD74 | GO:0043123 | positive regulation of I-kappaB kinase/NF-kappaB signaling | 24942581 |
| Tgene | CD74 | GO:0043410 | positive regulation of MAPK cascade | 24942581 |
| Tgene | CD74 | GO:0043518 | negative regulation of DNA damage response, signal transduction by p53 class mediator | 17045821 |
| Tgene | CD74 | GO:0045657 | positive regulation of monocyte differentiation | 24942581 |
| Tgene | CD74 | GO:0045893 | positive regulation of transcription, DNA-templated | 24942581 |
| Tgene | CD74 | GO:0046598 | positive regulation of viral entry into host cell | 24942581 |
| Tgene | CD74 | GO:0050731 | positive regulation of peptidyl-tyrosine phosphorylation | 17045821 |
| Tgene | CD74 | GO:0051290 | protein heterotetramerization | 24942581 |
| Tgene | CD74 | GO:0070374 | positive regulation of ERK1 and ERK2 cascade | 17045821|24942581 |
| Fusion gene information from three resources (ChiTars (NAR, 2018), tumorfusions (NAR, 2018), Gao et al. (Cell, 2018)) * All genome coordinats were lifted-over on hg19. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| Data type | Source | Cancer type | Sample | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| TCGA | RV | LUAD | TCGA-91-6835-01A | C1QA | chr1 | 22965442 | + | CD74 | chr5 | 149792314 | - |
| * LD: Li Ding group's fusion gene list RV: Roel Verhaak group's fusion gene list ChiTaRs fusion database |
| Open reading frame (ORF) analsis of fusion genes based on Ensembl gene isoform structure. * Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser. |
| ORF | Henst | Tenst | Hgene | Hchr | Hbp | Hstrand | Tgene | Tchr | Tbp | Tstrand |
| 5CDS-5UTR | ENST00000374642 | ENST00000377795 | C1QA | chr1 | 22965442 | + | CD74 | chr5 | 149792314 | - |
| 5CDS-5UTR | ENST00000374642 | ENST00000353334 | C1QA | chr1 | 22965442 | + | CD74 | chr5 | 149792314 | - |
| 5CDS-5UTR | ENST00000374642 | ENST00000524315 | C1QA | chr1 | 22965442 | + | CD74 | chr5 | 149792314 | - |
| 5CDS-5UTR | ENST00000374642 | ENST00000009530 | C1QA | chr1 | 22965442 | + | CD74 | chr5 | 149792314 | - |
| 5CDS-5UTR | ENST00000402322 | ENST00000377795 | C1QA | chr1 | 22965442 | + | CD74 | chr5 | 149792314 | - |
| 5CDS-5UTR | ENST00000402322 | ENST00000353334 | C1QA | chr1 | 22965442 | + | CD74 | chr5 | 149792314 | - |
| 5CDS-5UTR | ENST00000402322 | ENST00000524315 | C1QA | chr1 | 22965442 | + | CD74 | chr5 | 149792314 | - |
| 5CDS-5UTR | ENST00000402322 | ENST00000009530 | C1QA | chr1 | 22965442 | + | CD74 | chr5 | 149792314 | - |
Top |
FusionProtFeatures for C1QA_CD74 |
| Main function of each fusion partner protein. (from UniProt) |
| Hgene | Tgene |
| C1QA | CD74 |
| C1q associates with the proenzymes C1r and C1s to yieldC1, the first component of the serum complement system. Thecollagen-like regions of C1q interact with the Ca(2+)-dependentC1r(2)C1s(2) proenzyme complex, and efficient activation of C1takes place on interaction of the globular heads of C1q with theFc regions of IgG or IgM antibody present in immune complexes. |
| Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at . * Minus value of BPloci means that the break pointn is located before the CDS. |
| - In-frame and retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
| - In-frame and not-retained protein feature among the 13 regional features. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Protein feature | Protein feature note |
Top |
FusionGeneSequence for C1QA_CD74 |
| For in-frame fusion transcripts, we provide the fusion transcript sequences and fusion amino acid sequences. (nt: nucleotides, aa: amino acids) |
| * Fusion amino acid sequences. |
| * Fusion transcript sequences (only coding sequence (CDS) region). |
| * Fusion transcript sequences (Full-length transcript). |
Top |
FusionGenePPI for C1QA_CD74 |
| Go to ChiPPI (Chimeric Protein-Protein interactions) to see the chimeric PPI interaction in . |
| Protein-protein interactors with each fusion partner protein in wild-type (BIOGRID-3.4.160) |
| Hgene | Hgene's interactors | Tgene | Tgene's interactors |
| C1QA | CRP, DCN, C1S, C1R, FN1, PPP1CA, PPP1CC, APOA1, HIPK3, SLC25A47, BAG6, UBQLN2, SGTA, PIAS2, UBQLN1, GNPNAT1, RAC1, HSPB2, NLGN3 | CD74 | MIF, CD74, APP, HADHA, LAMTOR5, MAP3K1, TM4SF20, COPG1, COPG2, HLA-DPB1, HLA-DQA1, CD44 |
| - Retained PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Still interaction with |
| - Lost PPIs in in-frame fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
| - Retained PPIs, but lost function due to frame-shift fusion. |
| Partner | Gene | Hbp | Tbp | ENST | Strand | BPexon | TotalExon | Protein feature loci | *BPloci | TotalLen | Interaction lost with |
Top |
RelatedDrugs for C1QA_CD74 |
| Drugs targeting genes involved in this fusion gene. (DrugBank Version 5.1.0 2018-04-02) |
| Partner | Gene | UniProtAcc | DrugBank ID | Drug name | Drug activity | Drug type | Drug status |
| Hgene | C1QA | P02745 | DB00002 | Cetuximab | Complement C1q subcomponent subunit A | biotech | approved |
| Hgene | C1QA | P02745 | DB00051 | Adalimumab | Complement C1q subcomponent subunit A | biotech | approved |
| Hgene | C1QA | P02745 | DB00054 | Abciximab | Complement C1q subcomponent subunit A | biotech | approved |
| Hgene | C1QA | P02745 | DB00073 | Rituximab | Complement C1q subcomponent subunit A | biotech | approved |
| Hgene | C1QA | P02745 | DB00005 | Etanercept | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Hgene | C1QA | P02745 | DB00056 | Gemtuzumab ozogamicin | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Hgene | C1QA | P02745 | DB00072 | Trastuzumab | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Hgene | C1QA | P02745 | DB00074 | Basiliximab | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Hgene | C1QA | P02745 | DB00075 | Muromonab | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Hgene | C1QA | P02745 | DB00078 | Ibritumomab tiuxetan | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Hgene | C1QA | P02745 | DB00081 | Tositumomab | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Hgene | C1QA | P02745 | DB00087 | Alemtuzumab | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Hgene | C1QA | P02745 | DB00095 | Efalizumab | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Hgene | C1QA | P02745 | DB00108 | Natalizumab | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Hgene | C1QA | P02745 | DB00110 | Palivizumab | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Hgene | C1QA | P02745 | DB00112 | Bevacizumab | Complement C1q subcomponent subunit A | biotech | approved|investigational |
| Hgene | C1QA | P02745 | DB00092 | Alefacept | Complement C1q subcomponent subunit A | biotech | approved|investigational|withdrawn |
Top |
RelatedDiseases for C1QA_CD74 |
| Diseases associated with fusion partners. (DisGeNet 4.0) |
| Partner | Gene | Disease ID | Disease name | # pubmeds | Source |
| Hgene | C1QA | C0017661 | IGA Glomerulonephritis | 2 | CTD_human |
| Hgene | C1QA | C0015230 | Exanthema | 1 | CTD_human |
| Hgene | C1QA | C0017662 | Glomerulonephritis, Membranoproliferative | 1 | CTD_human |
| Hgene | C1QA | C0020951 | Immune Complex Diseases | 1 | CTD_human |
| Hgene | C1QA | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
| Hgene | C1QA | C0024141 | Lupus Erythematosus, Systemic | 1 | CTD_human |
| Hgene | C1QA | C0036341 | Schizophrenia | 1 | PSYGENET |
| Tgene | CD74 | C0007131 | Non-Small Cell Lung Carcinoma | 1 | CTD_human |
| Tgene | CD74 | C0023893 | Liver Cirrhosis, Experimental | 1 | CTD_human |
| Tgene | CD74 | C0162557 | Liver Failure, Acute | 1 | CTD_human |
| Tgene | CD74 | C1458155 | Mammary Neoplasms | 1 | CTD_human |
Copyright 2018-Present -The University of Texas Health Science Center at Houston (UTHealth)
|